²Ä¥|¤Q¤­¨÷²Ä¥|´Á 113¦~4¤ë1¤éµo¥Z
ªÍÀù¶Eªv·s¶i®i
¯×ªÕ²Ó­M¡Ð½Õ±±¨­Åé¥\¯àªº·s­n¨¤
¡·ªø©°¤j¾Ç¥Í²zº[ÃIJz¾Ç¬ì ¿c¥D´Ü §U²z±Ð±Â
ªÎ­D¤w¦¨¬°¶}µo°ê®a¤@­ÓÄY­«ªº°·±d°ÝÃD¡C²{¥N¤H½ÍªÎ­D°ÝÃD¡A¤£¶È¶È¥u¬O¬°¤F´îªÎ¬üÆ[¡A¦Ó¬O¦]¬°ªÎ­D·|¤Þ°_¤@¨Ç¬ÛÃö¯e¯f¡A¨Ò¦p¤ß¦åºÞ¯fÅܤο}§¿¯fµ¥¡A¹ï©ó°ê¤H°·±d»P¥Í¬¡«~½è¼vÅT¬Æ¹d¡C±q³Ìªñ°·«O§½¤½§G¥h¦~¥ÎÃıƦW¡A¤T°ª¥ÎÃÄ¡]°ª¦åÀ£¡B°ª¦å¯×¡B°ª¦å¿}¡^¥]¿ì«e¤T¦W¡A§Y¥i¬Ý¥X³o¨Ç¯e¯f¤w¦¨¬°²{¥NªÀ·|ªºÂåÀø­t¾á¡CµM¦Ó¡A¥Ñ©ó¶¼­¹²ßºD¡]³t­¹©±¥|³BªL¥ß¡^»P¥Í¬¡¤è¦¡¡]¹B°Ê¶q´î¤Ö¡A¾n¨¬ºô©@»P¦uµÛ¹qµø¡B¹q¸£«e¡^ªº§ïÅÜ¡AªÎ­Dµo¥Í¤w¦³¦~»´¤ÆªºÁͶաA¹L¥h¦b¤¤¦Ñ¦~¤H±`¨£ªº¤ß¦åºÞ©Î¥NÁ¯e¯f¡A²{¦b«h¦³¦~»´¤Æªº²{¶H¡A¥i¨£ªÎ­D°ÝÃD½T¹ê­È±o­«µø¡C
¡@¡@¦Ó½Í¨ìªÎ­D¡A¦ÛµM¤£¯à¤£½Í¯×ªÕ²Ó­M ( Adipocyte or fat cell )¡A¦]¬°ªÎ­D¡A§Y¬O¯×ªÕ²Ó­M¤º°ï¿n¤T»Ä¥Ìªoà­ ( Triacylglycerol ) ¼W¤j ( Hypertrophy ) ªºµ²ªG¡A¦Ó¯×ªÕ²Ó­Mªº¼W¤j¡A»P¨ä¥\¯à²§±`¦³²ö¤jªºÃöÁp¡C¥¿±`¯×ªÕ²Ó­Mªº¥\¯à¨ü¨ì¶i­¹¡B²üº¸»X¤Î¯«¸g¨t²Îªº½Õ±±¡G¨Ò¦p¯Ø®q¯À ( Insulin ) ¥i«P¶i¯×ªÕ¦X¦¨¡B§í¨î¯×ªÕ¤À¸Ñ¡B¨Ã«P¶i¦å¿}ªº§l¦¬¡F¦b°§¾jª¬ºA¤U¡A¯×ªÕ²Ó­MÀx¦sªº¤T»Ä¥Ìªoà­¥i³Q¤À¸ÑÄÀ¥X¯×ªÕ»Ä ( Fatty acids )¡A¨Ñ²Ó­M¤§¯à¶q¨Ó·½¡Cªø¤[¥H¨Ó¯×ªÕ²Ó­M¶È¶È³Q»{¬°¬OÀx¦s¹L¦h¯à¶q¤§ÀxÂëǡCµM¦Óªñ¦~ªº¬ã¨sµ²ªGµo²{¡A¨ä¹ê¯×ªÕ²Ó­M¤Àªc³\¦h­«­nªº³J¥Õ¦]¤l¡A¯à°÷¥D°Ê½Õ±±¨­Åé¨ä¥L²Õ´©Î¾¹©xªº¥Í²z¥\¯à¡C¨Ò¦p½G¨­¯À ( Leptin ) ¯à§í¨î­¹¼¤¡A¯×Áp¯À ( Adiponectin ) ¯à«P¶i¦Ù¦×²Ó­M¹ï©ó¯Ø®q¯Àªº±Ó·P ( Sensitivity )¡A¦Ó§Ü¯Ø®q¯À¿E¯À ( Resistin ) «h¨ã¦³»P¯×Áp¯À¬Û¤Ïªº¥\¯à¡C¥t¥~ªÎ­D³y¦¨¯×ªÕ²Ó­M¤Àªc§ó¦h¡§«Pµoª¢²Ó­M¿E¯À¡§ ( Proinflammatory cytokines ) ¦p TNF-£\ƒÑ (Tumor necrosis factor-£\ƒÑ)¡BIL-6( Interleukin 6 ) ¥H¤Î¤@¨ÇÁͤƯÀ ( Chemokines ) µ¥¡A¥ç³Q´£¥X¬O³y¦¨¯Ø®q¯Àªý§Ü ( Insulin resistance ) ªº­ì¦]¡C¦]¦¹¡A¯×ªÕ²Õ´¤w³Q»{¬°¬O­Ó¤º¤Àªc¾¹©x( Endocrine organ ) ¡A³\¦h¬ã¨s³æ¦ì­P¤O©ó¤F¸Ñ§ó¦h¯×ªÕ²Ó­M¤Àªcª«½è¹ï©ó¥Í²zªº¼vÅT¡C¥»¤å¤¶²Ð´X­Ó³Ìªñµo²{ªº¯×ªÕ²Ó­M¤Àªcª«½è¤Î¨ä¥\¯à¡A´Á¯à´£¨ÑŪªÌ¹ï¯×ªÕ²Ó­M§ó¦hªº»{ÃÑ¡C
1.¯×½è¯À( Lipokine)
¯×ªÕ²Ó­M¤Àªc³J¥Õ¦]¤l¤w¤£µ}©_¡I¬ü°ê«¢¦ò¤j¾Ç¤½½Ã¾Ç°| Hotamisligil ¹Î¶¤¡A¤Q¦h¦~«eµoªí¯×ªÕ²Ó­M¤Àªc¸~½FÃa¦º¦]¤l (TNF)ƒÑ¡A¬OªÎ­D¤Þ°_¤§¯Ø®q¯Àªý§Ü»P¿}§¿¯fªº­ì¦]¤§¤@¡F¥h¦~ ( 2008 ) µoªí¦b Cell ´Á¥Zªº¤å³¹«ü¥X¡A¯×ªÕ²Ó­M¥»¨­¥i¥H»s³y¤Î¤Àªc¤@Ãþ¥Ñ¯×½è²Õ¦¨ªº²üº¸»X[1]¡C¥Ñ©ó¥ý«e¯×ªÕ²Ó­M¤Àªc¤§³J¥Õ¦]¤l¡A³QºÙ¬° Adipokine (§Y Adipo + Cytokine) ¡A¦]¦¹§@ªÌºÙ·sµo²{ªº²üº¸»X¬°¡§lipokine¡§¡C§Q¥Î¯×½èÅé¾Ç ( Lipomics ) »P¦Ñ¹«°ò¦]­ç°£ ( Gene knockout ) §Þ³N¡A¦¹¹Î¶¤µo²{¡A·í¦Ñ¹«¦]¬°°ò¦]­ç°£¤@­Ó¯à±N¯×½è¦s¤J¯×ªÕ²Ó­Mªº­«­n³J¥Õ¡A¦]¦ÓµLªk±N¨Ó¦Û©ó­¹ª«ªº¯×½è¡A¦s¤J¯×ªÕ²Ó­Mªº±¡ªp¤U¡A¯×ªÕ²Ó­M¥»¨­·|¦X¦¨¨Ã¤Àªc¤@ºØ¯×½è¡Ð´ÄÃq»Äà­ (C16:1n7-palmitoleate)¡C¦³§O©ó±q­¹ª«Äá¨ú±o¨ìªº¯×ªÕ»Ä·|³y¦¨¦Ù¦×»P¨xŦªº¯Ø®q¯Àªý§Ü¡A³oºØ´ÄÃq»Äà­¯à«P¶i¯Ø®q¯Àªº¥\¯à¡C³oºØ¯×ªÕ²Ó­M¥»¨­¦X¦¨(De novo lipogenesis) ªº´ÄÃq»Äà­¡A¦b¤j¶qÄá¨ú¯×ªÕ­¹ª«ªº±¡ªp·|¨ü¨ì§í¨î¡A³o¤]¥¿¬O°ò¦]­ç°£¦Ñ¹«¥i¥H§Ü©Ú¥Ñ©ó°ª¯×ªÕ¶¼­¹©Ò¤Þ°_ªº¿}§¿¯f©Î¯×ªÕ¨xªº­ì¦]¡C³o¶µµo²{´£¨Ñ¤@­Ó·sªºªvÀø©Î¹w¨¾ªº¤è¦V¤D´N¬O¡G«P¶i¯×ªÕ²Ó­M¦Û»s¡§¦n¡¨ªº¯×ªÕ¡C
2. µø¶À¾JªþµÛ³J¥ÕRBP-4 (Retinol binding protein-4)
·í§Ú­Ì¶i­¹«á¡A¦å¿}¤É°ª·|¨ë¿E¯ØŦ¤Àªc¯Ø®q¯À¡C¯Ø®q¯ÀÂǥѫP¶i¦Ù¦×»P¯×ªÕ²Ó­Mªº¸²µå¿}Âà¹B¤l 4(Glucose transporter-4, ²ºÙGlut4) ¦Ü²Ó­M½¤¡A±N¦å¿}¥Ñ¦å²G¹B°e¦Ü²Ó­M¤º¡A¥H¥NÁ¹L°ªªº¦å¿}¡CÁöµMÅ餺ªº¦å¿}¥D­n¥Ñ¦Ù¦×²Ó­M¥NÁ¡A¦ý¦bªÎ­D©Î¿}§¿¯f±w«oµo²{¡AGlut4 ªºªí²{³º¦b¯×ªÕ²Ó­M¡A¦Ó«D¦b¦Ù¦×²Ó­Mªºªí²{´î¤Ö¡C³o¬O­Ó¦³½ìªºµ²ªG¡G¬JµM¦Ù¦×²Ó­M¬°¦å¿}¥D­n¥NÁª̡A¯×ªÕ²Ó­Mªº Glut4 ´î¤ÖÅãµM¤£¯à¸ÑÄÀ¿}§¿¯f±w°ª¦å¿}ªº²{¶H¡C¦p¦¹¤@¨Ó¦bªÎ­D©Î¿}§¿¯f±wªº¯×ªÕ²Ó­M Glut4 ªºªí²{­°§C¡A¦³¤°»ò·N¸q©O¡H¬°¸Ñµª³o°ÝÃD¡A«¢¦ò¤j¾ÇÂå¾Ç°|ªº Barbara Kahn ¹Î¶¤¿ï¾Ü©Ê­ç°£¦Ñ¹«¯×ªÕ²Ó­Mªº Glut4¡Aµ²ªG¦Ñ¹«¦b¦Ù¦×»P¨xŦ²£¥Í¯Ø®q¯Àªý§Ü²{¶H¡AÅãµM¯×ªÕ²Ó­M Glut4 ­°§C¡A¥i²£¥Í¯S©w°T®§¥h¼vÅT¦Ù¦×»P¨xŦªº¥\¯à[2]¡CÀˬd¦¹¦Ñ¹«µo²{¡A¦h¼Æ¤wª¾ªº¯×ªÕ²Ó­M¤Àªc¦]¤l¨ÃµL§ïÅÜ¡AµM¦Ó¯×ªÕ²Ó­M¤Àªc­t³d¶Ç°eºû¥Í¯À A( Retinol ) ªº³J¥Õ RBP-4¡A¨ä²£¶q»P¤Àªc³£¼W¥[¡C§@ªÌ¶i¤@¨Bµo²{ RBP-4 ¥i¥H§í¨î¯Ø®q¯À¥\¯à¡A¥BªÎ­D©Î¿}§¿¯f±w¦³¸û°ªªº RBP-4¡C¦p¦¹¡AÁöµM¦Ù¦×²Ó­Mªº Glut4 ­t³d¹B°e¦å¿}¡A¦ý¯×ªÕ²Ó­Mªº Glut4 ªí²{¶q«o¥i½Õ¸`¯S©wªºÄÀ©ñ¦]¤l(¨Ò¦p RBP-4)¨Ó¼vÅT¦Ù¦×»P¨xŦ¹ï¸²µå¿}¥NÁªº¥\¯à¡C
3. Still unknown- ¯×ªÕ²Ó­M»PµÇ¤W¸¢ (Adrenal gland)
¦p«e©Ò­z¡AªÎ­D¥i¤Þµo³\¦h¥NÁ¯e¯f¡AµM¦Ó³y¦¨¦º¤`ªº­ì¦]¥D­n¨Ó¦Û©ó¨Öµo¤ß¦åºÞ¯e¯f¡A¦]¦¹ªÎ­D¦p¦ó¤Þ°_°ª¦åÀ£«K¦¨¬°¨ä¤¤¤@­«­n½ÒÃD¡C¦Ó³z¹L¯×ªÕ²Ó­M¤Àªc¤§ª«½è¼vÅT¨ä¥L¾¹©x¥\¯à¡A´£¨Ñ¤@­Ó¥i¯àªº¸ÑÄÀ¡C¹L¥hªº¬ã¨s¤wª¾¯×ªÕ²Ó­M¥i¼vÅT»P¥NÁ¬ÛÃöªº¦Ù¦×¡B¨xŦ¥\¯à¡A¥ç»P§K¬Ì²Ó­M¤§¶¡¦³¥æ¤¬§@¥Î¡C¦Ó³Ìªñªº¬ã¨sµo²{¡A¯×ªÕ²Ó­M¥ç¥i¤Àªc¤@ºØ©|¥¼§¹¥þ©ú¥Õªº¦]¤l¡A¯à«P¶iµÇ¤W¸¢¦X¦¨¤Î¤ÀªcÄqª«¥Ö½èà¬(mineralocorticoid) ¡A¤×¨ä¬OîÇÃþ¯×¾J (aldosterone)(for review[3])¡C¹L¦hªºÄqª«¥Ö½è଱N³y¦¨°ª¦åÀ£¡A¦ÓªÎ­Dªº¤H±`¦ñÀH¦³¸û°ªªºîÇÃþ¯×¾J¡C¦]¦¹¡A¦p¯à½T»{¦¹¯×ªÕ²Ó­M¤Àªc¦]¤l¬°¦ó¡A±N¦³§U©óªvÀøªÎ­D¤Þ°_¤§°ª¦åÀ£µ¥¯e¯f¡C
Reference
[1] Cao, H., Gerhold, K., Mayers, J. R., Wiest, M. M., Watkins, S. M., and Hotamisligil, G. S. (2008) Cell 134(6), 933-944
[2] Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., and Kahn, B. B. (2005) Nature 436(7049), 356-362
[3] Ronconi, V., Turchi, F., Bujalska, I. J., Giacchetti, G., and Boscaro, M. (2008) Trends Endocrinol Metab 19(3), 100-103

         
 
«Ê­±¬G¨Æ
¬Ý¤£¨£ªºÁô§Î±þ¤â¡uªÍÀù¡vµL©Ò¹P§Î¡ãªÍÀù¿zÀË LDCT ¤¶²Ð
¦¸¥@¥N°ò¦]ÀË´ú¤¶²Ð
ªÍÀù¼Ð¹vÃĪ«ªvÀø¡ã°·«O·sÃÄ tepotinib
ªÍÀùºë·ÇªvÀø·s§Q¾¹¡ã§ÜÅéÃĪ«½Æ¦XÅé (ADC)
Âå¾Ç³ø¾É
¦Ð²y¥¿Éq¡ã²¤¶¦Ð²y¬ÛÃö¹B°Ê¶Ë®`»P·sÀøªk
¤ßÆFÂIºw
Å@²z¡A©l²×¬O¨º³sµ²ªº¾ô¼Ù
¤¤Âå³ø¾É
±z¦³¦Û«ß¯«¸g¥¢½Õ¶Ü¡H¤¤Âå§U±z§ä¦^¨­¤ßªº¥­¿Å
¾i¥Í¤å¤Æ§ø³ø¾É
¾i¥Í§øªº¸ô
¨àµ£ÂåÀø
·s¥Í¨à¤p¤U¤Ú¡BÃEµõ¡B©I§l¹Dªý¶ë¡@²¤¶¡u¥Öº¸Ã¹»«¯g­Ô¸s¡vªº·s«¬¤â³NÀøªk
¥»¤ë¥DÃD
ªÍÀù¶Eªv·s¶i®i
µJÂI¸ÜÃD
´c©Ê¸£½Fªº³Ð·s§Æ±æ¡ãÃþ¯f¬r©`¦Ì¸üÅé»P°ò¦]ÀRÀq
ªÓÃö¸`Ãè³N«á´_°··sÆ[©À¡ã´£¦­´_°·¥i´£¦­±d´_¡A¦^Âk¥¿±`¥Í¬¡